Mga Batayang Estadistika
| LEI | 529900WCUY9ZAHMRV489 |
| CIK | 1466301 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Clovis Oncology Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 11, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35347 Clovis Oncology, Inc. (Exact name of registrant as specifi |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 10, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 POS AM As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: CLOVIS ONCOLOGY, INC., et al.,1 Debtors. Chapter 11 Case No. 22-11292 (JKS) (Jointly Administered) Re: D.I. 616, 823, 848, 884 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER (I) APPROVING DISCLOSURE STATEMENT ON A FINAL BASIS AND (II) CONFIRMING THE THIRD AMENDED JOINT CHAPTER 11 PLAN OF LIQUIDATION OF |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 S-8 POS As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| June 30, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case Exhibit 99.2 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Reporting Method: Industry Classification: Accrual Basis Cash Basis Debtor’s Full-Time Employees (curre |
|
| June 30, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Employees |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 30, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case EX-99.3 Exhibit 99.3 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Emplo |
|
| June 2, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case EX-99.2 Exhibit 99.2 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2023 Petition Date: 12/11/2022 Months Pending: 5 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Emp |
|
| June 2, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2023 Petition Date: 12/11/2022 Months Pending: 5 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Employee |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| June 2, 2023 |
DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case EX-99.3 Exhibit 99.3 DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2023 Petition Date: 12/11/2022 Months Pending: 5 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Employees (current): 8 Debtor’s Fu |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| May 3, 2023 |
EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2023 Petition Date: 12/11/2022 Months Pending: 4 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis ☒ Cash Basis ☐ Debtor’s Full-Time Em |
|
| May 3, 2023 |
EX-99.3 Exhibit 99.3 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2023 Petition Date: 12/11/2022 Months Pending: 4 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis ☒ Cash Basis ☐ Debtor’s Full-Ti |
|
| May 3, 2023 |
EX-99.2 Exhibit 99.2 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2023 Petition Date: 12/11/2022 Months Pending: 4 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-T |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 6, 2023 |
EX-10.1 Exhibit 10.1 Execution Version ASSET PURCHASE AGREEMENT by and among Clovis Oncology, Inc., and pharma& Schweiz GmbH Dated as of April 5, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Construction 18 ARTICLE 2 SALE AND PURCHASE OF ASSETS; LIABILITIES 19 2.1 Sale of Purchased Assets 19 2.2 Liabilities 20 2.3 Consideration 21 2.4 Closing 24 2.5 No Offset 24 A |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 5, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 31, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case EX-99.2 Exhibit 99.2 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/28/2023 Petition Date: 12/11/2022 Months Pending: 3 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Tim |
|
| March 31, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case EX-99.3 Exhibit 99.3 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/28/2023 Petition Date: 12/11/2022 Months Pending: 3 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Emp |
|
| March 31, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/28/2023 Petition Date: 12/11/2022 Months Pending: 3 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Employee |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 2, 2023 |
EX-99.1 Exhibit 99.1 Case 22-11292-JKSDoc 413Filed 03/01/23Page 1 of 21 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re.Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 01/31/2023 Petition Date: 12/11/2022 Months Pending: 2 Industry Classification: 3 2 5 4 Reporting Method: Ac |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 2, 2023 |
EX-99.2 Exhibit 99.2 Case 22-11292-JKSDoc 415Filed 03/01/23Page 1 of 21 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re.Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 01/31/2023 Petition Date: 12/11/2022 Months Pending: 2 Industry Classification: 3 2 5 4 Reporting |
|
| March 2, 2023 |
EX-99.3 Exhibit 99.3 Case 22-11292-JKSDoc 414Filed 03/01/23Page 1 of 21 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re.Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 01/31/2023 Petition Date: 12/11/2022 Months Pending: 2 Industry Classification: 3 2 5 4 Reporting Metho |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| February 13, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case EX-99.2 Exhibit 99.2 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Tim |
|
| February 13, 2023 |
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Employee |
|
| February 13, 2023 |
EX-99.3 Exhibit 99.3 UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Time Emp |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| February 10, 2023 |
SC 13G/A 1 p23-0725sc13ga.htm CLOVIS ONCOLOGY, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Chec |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2023 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission F |
|
| January 12, 2023 |
EX-10.1 Exhibit 10.1 Execution Version SECURED SUPERPRIORITY DEBTOR-IN-POSSESSION FINANCING AGREEMENT dated as of January 6, 2023 among CLOVIS ONCOLOGY, INC., as Borrower and Company, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, THE VARIOUS LENDERS FROM TIME TO TIME PARTY HERETO AND TOP IV TALENTS, LLC, as Administrative Agent TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 2 S |
|
| January 12, 2023 |
EX-10.2 Exhibit 10.2 EXECUTION VERSION PLEDGE AND SECURITY AGREEMENT dated as of January 6, 2023 among EACH OF THE GRANTORS PARTY HERETO and TOP IV TALENTS, LLC, as Administrative Agent TABLE OF CONTENTS Page Section 1. DEFINITIONS; GRANT OF SECURITY 1 1.1 General Definitions 1 1.2 Definitions; Interpretation 7 Section 2. GRANT OF SECURITY 8 2.1 Grant of Security 8 2.2 Certain Limited Exclusions 9 |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 16, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| December 19, 2022 |
EX-10.1 Exhibit 10.1 Annex B DIP TERM SHEET CLOVIS ONCOLOGY, INC. This summary of terms and conditions (this “DIP Term Sheet”) sets forth the material terms of a proposed debtor-in-possession financing facility that the DIP Lenders (as defined below) are contemplating providing to Clovis Oncology, Inc. (the “Borrower”) and the Guarantors referenced below as debtors and debtors in possession (toget |
|
| December 13, 2022 |
EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[****]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EXECUTION VERSION CONFIDENTIAL PURCHASE AND ASSIGNMENT AGREEMENT THIS PURCHASE AND ASSIGNMENT AGREEMENT (this |
|
| December 13, 2022 |
EX-99.1 Exhibit 99.1 Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 Receives Commitment for up to $75 Million in Debtor-in-Possession Financing BOULDER, Colo., December 11, 2022 — Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2022 |
EX-10.2 Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[****]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Execution Version December 11, 2022 CONFIDENTIAL Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulde |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 1, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35 |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2022 |
Exhibit 99.1 Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs ? First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity ? Confirmed partial response in one patient in the lowest (3.7 GBq) dose co |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 6, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2022 |
Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc. Exhibit 3.1 CERTIFICATE OF CORRECTION TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLOVIS ONCOLOGY, INC. Clovis Oncology, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the corporation is Clovis Oncology, Inc. (the ?Company?). 2. The Company?s Amended and Restated Certific |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2022 |
Exhibit 99.1 Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs ? ATHENA study evaluating Rubraca? (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and al |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted |
|
| April 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2022 |
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones Exhibit 99.1 Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones ? Three top-line Phase 3 data read-outs for Rubraca expected in 2022, with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy ? Phase 1/2 LuMIERE study of targeted radiotherapy candidate FAP-2286 ongoing; initial Phase 1 data expected at nuc |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2022 |
CLVS / Clovis Oncology Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Clovis Oncology Inc. Title of Class of Securities: Common Stock CUSIP Number: 189464100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 8, 2022 |
CLVS / Clovis Oncology Inc / BlackRock Inc. Passive Investment us1894641000020822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) CLOVIS ONCOLOGY INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 189464100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 10, 2022 |
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 Exhibit 99.1 Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 ? Estimated $35.5M - $36.1M in Rubraca? (rucaparib) global sales for Q4 2021 and $148.3M?$148.9M for FY 2021 ? Continuing impact on ovarian cancer diagnoses and treatments from COVID-19 ? Q4/FY 2021 Operating Results call planned for February 23, 2022 ? Company to present at J.P. Morgan H |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| November 29, 2021 |
Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, Colorado 80301 Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, Colorado 80301 November 29, 2021 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Clovis Oncology, Inc. ? Request for Withdrawal of Registration Statement on Form S-3 (File No. 333-251120) Ladies and Gentleman: Pursuant to Rule 477 promulgated |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2021 |
List of Subsidiaries of Clovis Oncology, Inc. ? Exhibit 21.1 List of Subsidiaries of Clovis Oncology, Inc. Name: Jurisdiction of Organization: Clovis Oncology UK Limited United Kingdom Clovis Oncology IT Srl Italy Clovis Oncology Switzerland GmbH Switzerland Clovis Oncology France SAS France Clovis Oncology Spain SL Spain Clovis Oncology Germany GmbH Germany Clovis Oncology Denmark ApS Denmark Clovis Oncology Ireland Limited Ireland ? |
|
| November 3, 2021 |
Clovis Oncology Announces Third Quarter 2021 Operating Results Exhibit 99.1 Clovis Oncology Announces Third Quarter 2021 Operating Results ? $37.9M in Rubraca? (rucaparib) global net product revenues for Q3 2021, up 3% over Q2 2021 and down 2% from Q3 2020 ? Three top-line Phase 3 data read-outs for Rubraca expected in 2022 with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy ? Phase 1 LuMIERE study of t |
|
| October 12, 2021 |
CLVS / Clovis Oncology Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Clovis Oncology Inc. Title of Class of Securities: Common Stock CUSIP Number: 189464100 Date of Event Which Requires Filing of this Statement: September 30, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| August 16, 2021 |
Exhibit 1.1 DISTRIBUTION AGREEMENT August 16, 2021 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Clovis Oncology, Inc., a Delaware corporation (the ?Company?), confirms its agreement with each of J.P. Morgan Securities LLC, and BofA Securities, Inc. as agent and/or principal under any Term |
|
| August 16, 2021 |
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program Exhibit 99.1 Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program BOULDER, Colo., August 16, 2021 ? Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (?SEC?) to renew its previously established ATM facility under which it may offer and sell, from time to time, additional shares of its |
|
| August 16, 2021 |
Up to $125,000,000 COMMON STOCK Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253485 Prospectus Supplement (To Prospectus dated May 7, 2021) Up to $125,000,000 COMMON STOCK We have entered into a distribution agreement with J.P. Morgan Securities LLC and BofA Securities, Inc., or the Agents, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In |
|
| August 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission F |
|
| August 4, 2021 |
Clovis Oncology, Inc. 2021 Employee Stock Purchase Plan ? Exhibit 10.44 CLOVIS ONCOLOGY, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. (b) The Co |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 4, 2021 |
Clovis Oncology, Inc. Amended and Restated 2020 Stock Incentive Plan. ? Exhibit 10.4 Clovis Oncology, Inc. Amended and Restated 2020 Stock Incentive Plan The Plan, originally adopted by the Board on April 22, 2020 and approved by the Company?s stockholders on June 4, 2020, is hereby amended and restated effective June 10, 2021. 1.Purpose. The purpose of the Plan is to assist the Company in attracting, retaining, motivating, and rewarding certain employees, officers, |
|
| August 4, 2021 |
Exhibit 99.2 Clovis Oncology Key Strategies August 4, 2021 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this presentation include, among o |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2021 |
Clovis Oncology Announces Second Quarter 2021 Operating Results Exhibit 99.1 Clovis Oncology Announces Second Quarter 2021 Operating Results ? $36.8M in Rubraca? (rucaparib) global net product revenues for Q2 2021, down 8% vs. Q2 2020, due to continuing impact of COVID-19 ? Phase 1/2 LuMIERE clinical study of FAP-2286 open for enrollment, first peptide-targeted radionuclide therapeutic candidate targeting FAP in clinical development ? Three top-line Phase 3 da |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 12, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 13, 2021 |
Exhibit 10.1 CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of July 12, 2021, and is between Clovis Oncology, Inc., a Delaware corporation (the ?Company?), and Ronit Simantov (?Indemnitee?). RECITALS A. Indemnitee?s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers |
|
| June 23, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2021 (June 10, 2021) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction |
|
| June 17, 2021 |
As filed with the Securities and Exchange Commission on June 17, 2021 As filed with the Securities and Exchange Commission on June 17, 2021 Registration No. |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| May 17, 2021 |
Clovis Oncology Announces At-The-Market Equity Offering Program Exhibit 99.1 Clovis Oncology Announces At-The-Market Equity Offering Program BOULDER, Colo., May 17, 2021 ? Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (?SEC?), under which it may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75,000,000 mil |
|
| May 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 17, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| May 17, 2021 |
Up to $75,000,000 COMMON STOCK Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253485 Prospectus Supplement (To Prospectus dated May 7, 2021) Up to $75,000,000 COMMON STOCK We have entered into a distribution agreement with J.P. Morgan Securities LLC and BofA Securities, Inc., or the Agents, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In a |
|
| May 17, 2021 |
EX-1.1 2 d178148dex11.htm EX-1.1 Exhibit 1.1 DISTRIBUTION AGREEMENT May 17, 2021 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Clovis Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement with each of J.P. Morgan Securities LLC, and BofA Securities, Inc. as agent a |
|
| May 5, 2021 |
Exhibit 10.41 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of this 4th day of May 2021, by and between Clovis Oncology, Inc., a Delaware corporation (the ?Company?), and Thomas C. Harding (the ?Employee?). W I T N E S S E T H : WHEREAS, Employee was employed by the Company as its Senior Vice President and Chief Scientific Officer; and WHEREAS, the C |
|
| May 5, 2021 |
As filed with the Securities and Exchange Commission on May 5, 2021 Registration No. |
|
| May 5, 2021 |
? Exhibit 10.42 CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of May 3, 2021, and is between Clovis Oncology, Inc., a Delaware corporation (the ?Company?), and Thomas C. Harding (?Indemnitee?). RECITALS A.Indemnitee?s service to the Company substantially benefits the Company. B.Individuals are reluctant to serve as directors or office |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| May 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2021 |
Clovis Oncology Announces First Quarter 2021 Operating Results Exhibit 99.1 Clovis Oncology Announces First Quarter 2021 Operating Results ? $38.1M in Rubraca? (rucaparib) global net product revenues for Q1 2021, down 11% vs. Q1 2020, due to continued headwinds from COVID-19 in the US and Europe ? Maintained US market share as US PARP inhibitor market impacted by COVID-19 ? Imaging and treatment INDs cleared by FDA for FAP-2286, a novel peptide-targeted radio |
|
| May 5, 2021 |
Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 May 5, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jordan Metoyer and Ada D. Sarmento Re: Clovis Oncology, Inc.?Request for Acceleration Registration Statement on Form S-3 (File No. 333-253485) Ladies and Gentlemen: Pursuant to Rule 461 promul |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 28, 2021 |
Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 April 28, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jordan Metoyer and Ada D. Sarmento Re: Clovis Oncology, Inc.?Request for Acceleration Registration Statement on Form S-3 (File No. 333-253485) Ladies and Gentlemen: Pursuant to Rule 461 pro |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted |
|
| April 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted |
|
| February 25, 2021 |
Exhibit 10.40 Execution Copy CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AND COLLABORATION AGREEMENT THIS LICENSE AND COLLABORATION AGREEMENT (the ?Agreement?) is made |
|
| February 25, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2021 |
EX-25.1 4 d326535dex251.htm EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trus |
|
| February 23, 2021 |
Clovis Oncology Announces 2020 Operating Results EX-99.1 Exhibit 99.1 Clovis Oncology Announces 2020 Operating Results • $164.5M in Rubraca® (rucaparib) global net product revenues for 2020, up 15% over 2019; $43.3M in Rubraca global net product revenues for Q4 2020, up 10% over Q4 2019 • Phase 1/2 LuMIERE study of FAP-2286, a targeted radiotherapy, planned to begin 1H 2021 • Top-line data from Phase 3 ATHENA trial of Rubraca as first-line maint |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2021 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Clovis Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Clovis Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value par value per share, of Clovis Oncol |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Clovis Oncology, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing of the Statement Check the appropriate box to des |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Clovis Oncology, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the u |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Clovis Oncology Inc. Title of Class of Securities: Common Stock CUSIP Number: 189464100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2021 (January 11, 2021) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorpor |
|
| January 11, 2021 |
EX-99.2 39th Annual J.P. Morgan Healthcare Conference January 12, 2021 Exhibit 99.2 To the extent that statements contained in this presentation are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this presentation include, among oth |
|
| January 11, 2021 |
Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020 EX-99.1 Exhibit 99.1 Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020 • Estimated $43.0M - $43.5M in Rubraca® (rucaparib) global sales for Q4 2020 and $164.2M - $164.7M for FY 2020 • Q4/FY 2020 Operating Results call planned for February 23, 2021 • Company to present at J.P. Morgan Healthcare Conference on Tuesday, January 12 BOULDER, Colo., January |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2020 (December 21, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorp |
|
| December 14, 2020 |
Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 December 14, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: David Gessert Re: Clovis Oncology, Inc.?Request for Acceleration Registration Statement on Form S-3 (File No. 333-251120) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the |
|
| December 4, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 4, 2020 Registration No. |
|
| November 27, 2020 |
EX-99.1 Exhibit 99.1 Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Boulder, CO, November 24, 2020 – Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that pursuant to the terms of that previously announced Exchange and Purchase Agreement, dated as of Novem |
|
| November 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2020 (November 27, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorp |
|
| November 17, 2020 |
Exhibit 4.1 EXECUTION VERSION CLOVIS ONCOLOGY, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of November 17, 2020 4.50% Convertible Senior Notes due 2024 TABLE OF CONTENTS Page ARTICLE I????DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 10 ARTICLE II????ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES 10 Secti |
|
| November 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 17, 2020 ( November 17, 2020 ) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of inco |
|
| November 5, 2020 |
EX-10.1 Exhibit 10.1 EXCHANGE AND PURCHASE AGREEMENT This Exchange and Purchase Agreement (this “Agreement”) is made and entered into as of November 4, 2020 by and among Clovis Oncology, Inc., a Delaware corporation (the “Company”), and each of the entities (each, a “Noteholder” and, collectively, the “Noteholders”) listed on Schedule “A” attached to this Agreement (collectively, “Schedule A”; the |
|
| November 5, 2020 |
Clovis Oncology Announces Third Quarter 2020 Operating Results EX-99.1 Exhibit 99.1 Clovis Oncology Announces Third Quarter 2020 Operating Results • $38.8M in Rubraca® (rucaparib) global sales for Q3 2020; net product revenue up 3% over Q3 2019 • Global net product revenue guidance provided for Q4 2020 in a range of $38M to $40M • Restructuring U.S. commercial organization to adopt hybrid strategy elevating digital programming and peer-to-peer interactions • |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2020 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| November 5, 2020 |
EX-4.1 Exhibit 4.1 CLOVIS ONCOLOGY, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of [ ], 2020 4.50% Convertible Senior Notes due 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 9 ARTICLE II ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES 10 Section 2.01 Designation and Am |
|
| November 5, 2020 |
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes EX-99.1 Exhibit 99.1 Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes Boulder, Colo., November 5, 2020 – Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on November 4, 2020 it entered into a privately negotiated exchange and purchase agreement (the “Agreement”) with a holder of its currently outstanding 4.50% Convertible Senior Notes due 2024 ( |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35 |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2020 (November 4, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorpor |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35347 C |
|
| August 7, 2020 |
Clovis Oncology, Inc. 2020 Stock Incentive Plan Exhibit 10.4 Clovis Oncology, Inc. 2020 Stock Incentive Plan 1.Purpose. The purpose of the Plan is to assist the Company in attracting, retaining, motivating, and rewarding certain employees, officers, directors, and consultants of the Company and its Affiliates and promoting the creation of long-term value for stockholders of the Company by closely aligning the interests of such individuals with |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2020 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 6, 2020 |
Clovis Oncology Announces Second Quarter 2020 Operating Results EX-99.1 Exhibit 99.1 Clovis Oncology Announces Second Quarter 2020 Operating Results • $39.9M in Rubraca® (rucaparib) global sales for Q2 2020 and $82.5M for H1 2020; net product revenue up 21% over Q2 2019 and 25% over H1 2019 • $261.4M in cash and cash equivalents at June 30, 2020; anticipated to fund operating plan into early 2022 • Rubraca approved in the U.S. as monotherapy treatment for pati |
|
| June 4, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 4, 2020 Registration No. |
|
| June 4, 2020 |
Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Restricted Stock Unit Agreement. EX-10.3 Exhibit 10.3 RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT Clovis Oncology, Inc. (the “Company”), pursuant to its 2020 Stock Incentive Plan (the “Plan”), hereby grants to the Holder the number of Restricted Stock Units set forth below, each Restricted Stock Unit being a notional unit representing the right to receive one share of Stock. The Restricted Stock Units are subject to all of t |
|
| June 4, 2020 |
Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Option Agreement. EX-10.2 Exhibit 10.2 OPTION GRANT NOTICE AND AGREEMENT Clovis Oncology, Inc. (the “Company”), pursuant to its 2020 Stock Incentive Plan (the “Plan”), hereby grants to the Holder the number of Options set forth below, each Option representing the right to purchase one share of Stock at the applicable Exercise Price (set forth below). The Options are subject to all of the terms and conditions set fo |
|
| June 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2020 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2020 (May 18, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) ( |
|
| May 21, 2020 |
Underwriting Agreement, dated May 18, 2020 EX-1.1 Exhibit 1.1 Clovis Oncology, Inc. 11,090,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement May 18, 2020 J.P. Morgan Securities LLC BofA Securities, Inc. c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Clovis Oncology, Inc., a Delaware corporation ( |
|
| May 21, 2020 |
Clovis Oncology Announces Proposed Offering of Common Stock EX-99.1 Exhibit 99.1 Clovis Oncology Announces Proposed Offering of Common Stock BOULDER, Colo., May 18, 2020 – Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock. Clovis Oncology intends to offer, subject to market and other conditions, $85 million of shares of its common stock in an underwritten registered public offering. In |
|
| May 21, 2020 |
Clovis Oncology Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 Clovis Oncology Announces Pricing of Public Offering of Common Stock BOULDER, Colo., May 18, 2020 – Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology also granted to the underwriter |
|
| May 19, 2020 |
11,090,000 Shares COMMON STOCK 424B5 1 d907223d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-235536 and 333-238463 Prospectus Supplement (To Prospectus dated December 30, 2019) 11,090,000 Shares COMMON STOCK We are offering 11,090,000 shares of our common stock as described in this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Se |
|
| May 18, 2020 |
S-3MEF As filed with the Securities and Exchange Commission on May 18, 2020 Registration No. |
|
| May 18, 2020 |
Subject to completion, dated May 18, 2020 424B5 1 d907223d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-235536 and 333-238463 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus is not an offer to sell these securities in any state or other jurisdiction where the offer or sale is not permitted. Subject to com |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35347 |
|
| May 5, 2020 |
Clovis Oncology Announces First Quarter 2020 Operating Results EX-99.1 Exhibit 99.1 Clovis Oncology Announces First Quarter 2020 Operating Results • $42.6M in Rubraca® (rucaparib) global sales for Q1 2020; net product revenue up 8% over Q4 2019 and up 29% over Q1 2019 • Supplemental NDA for Rubraca in patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer granted Priority Review by FDA with PDUFA date of May 15, 2020 • $228.4M i |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2020 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission File |
|
| April 24, 2020 |
DEFA14A 1 d911132ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| April 24, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2020 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 16, 2020 |
Amendment No. 1 to the Amended and Restated Bylaws of Clovis Oncology, Inc. EX-3.1 Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF CLOVIS ONCOLOGY, INC. April 14, 2020 The Amended and Restated Bylaws of CLOVIS ONCOLOGY, INC. (the “Company”), are hereby amended by adding the following Section 7.4 in Article VII thereof: “7.4 Exclusive Forum. Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the |
|
| April 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2020 (April 14, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporatio |
|
| April 14, 2020 |
Clovis Oncology Announces Debt Exchange Transaction EX-99.1 Exhibit 99.1 Clovis Oncology Announces Debt Exchange Transaction Boulder, Colo., April 14, 2020 – Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately negotiated exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021 (the “2021 Notes”). Pursuant to the exchange agreement, Clovis Oncology will issue to such holder o |
|
| February 26, 2020 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Clovis Oncology, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, $0.001 par value per share. The following summary describes our common stock and preferred stock and th |
|
| February 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2019. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35347 Clovi |
|
| February 24, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2020 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| February 24, 2020 |
Clovis Oncology Announces 2019 Operating Results EX-99.1 Exhibit 99.1 Clovis Oncology Announces 2019 Operating Results • Rubraca® (rucaparib) net product revenue totaled $143.0M for 2019 and $39.3M for Q4 2019 • Net product revenue for 2019 up 50% over 2018 • 46% reduction in net cash utilized in 2H 2019 compared to 1H 2019 • $296.7M in cash, cash equivalents and available for sale securities at December 31, 2019; continue to anticipate cash run |
|
| February 14, 2020 |
CLVS / Clovis Oncology, Inc. / D. E. SHAW & CO, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Clovis Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the S |
|
| February 14, 2020 |
Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| February 14, 2020 |
Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| February 14, 2020 |
CLVS / Clovis Oncology, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Clovis Oncology, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2019 Date of Event Which Requires |
|
| February 14, 2020 |
CLVS / Clovis Oncology, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Clovis Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2020 |
CLVS / Clovis Oncology, Inc. / Camber Capital Management LLC - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2020 |
CLVS / Clovis Oncology, Inc. / WHITEBOX ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
CLVS / Clovis Oncology, Inc. / ORBIMED ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| February 14, 2020 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2020 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 13, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2020 |
CLVS / Clovis Oncology, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Clovis Oncology Inc Title of Class of Securities: Common Stock CUSIP Number: 189464100 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| January 23, 2020 |
CLVS / Clovis Oncology, Inc. / Elk Creek Partners, LLC - ELK CREEK PARTNERS, LLC Passive Investment SC 13G/A 1 clvsa112320.htm ELK CREEK PARTNERS, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Clovis Oncology, Inc. (Name of Issuer) Common Stock par Value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this State |
|
| January 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2020 (January 7, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporat |
|
| January 8, 2020 |
Clovis Oncology Announces Debt Refinancing Transaction EX-99.1 Exhibit 99.1 Clovis Oncology Announces Debt Refinancing Transaction Boulder, CO, January 7, 2020 – Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the “Shares”) of its common stock at a price of $9.25 per share to a limited number of holders (the |
|
| January 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 7, 20 20 (January 7, 2020) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorpora |
|
| January 7, 2020 |
EX-99.1 Exhibit 99.1 Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019 • Estimated $38.3M - $39.3M in Rubraca® sales for Q4 2019 and $142.0M-$143.0M for FY2019 consistent with guidance • Q4/FY2019 Operating Results call planned for February 24, 2020 • sNDA for Rubraca in advanced prostate cancer submitted in mid-November 2019 • Company to present at J.P. Morgan H |
|
| January 7, 2020 |
17,777,679 shares COMMON STOCK 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235536 Prospectus Supplement (To Prospectus dated December 30, 2019) 17,777,679 shares COMMON STOCK We are offering 17,777,679 shares of our common stock as described herein, in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement and the accompanying prospectus at a price |
|
| December 27, 2019 |
CLVS / Clovis Oncology, Inc. CORRESP - - CORRESP 1 filename1.htm Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 December 27, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Mr. Chris Edwards Re: Clovis Oncology, Inc.—Request for Acceleration Registration Statement on Form S-3 (File No. 333-235536) Ladies and G |
|
| December 23, 2019 |
CLVS / Clovis Oncology, Inc. S-3/A - - S-3/A S-3/A Table of Contents As filed with the Securities and Exchange Commission on December 23, 2019 Registration No. |
|
| December 23, 2019 |
CLVS / Clovis Oncology, Inc. CORRESP - - CORRESP 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 December 23, 2019 VIA EDGAR Mr. |
|
| December 16, 2019 |
EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trustee as specified in its char |
|
| December 16, 2019 |
CLVS / Clovis Oncology, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 16, 2019 Registration No. |
|
| December 2, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| December 2, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) November 20, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| November 15, 2019 |
Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| November 15, 2019 |
CLVS / Clovis Oncology, Inc. / D. E. SHAW & CO, L.P. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Clovis Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 189464100 (CUSIP Number) November 5, 2019 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedule is filed: ¨ |
|
| November 15, 2019 |
Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| November 15, 2019 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| November 8, 2019 |
CLVS / Clovis Oncology, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on November 8, 2019 Registration No. |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| November 7, 2019 |
Clovis Oncology Announces Third Quarter 2019 Operating Results EX-99.1 Exhibit 99.1 Clovis Oncology Announces Third Quarter 2019 Operating Results • $37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year • Net product revenue increased 14% sequentially in Q3 2019 compared to Q2 2019, including sequential U.S. sales increase of 12% • Increased FY2019 global net product revenue guidance to $141M-$147M • Q3 2019 operating cash burn |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35 |
|
| September 10, 2019 |
CLVS / Clovis Oncology, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Clovis Oncology Inc Title of Class of Securities: Common Stock CUSIP Number: 189464100 Date of Event Which Requires Filing of this Statement: August 30, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R |
|
| September 5, 2019 |
CLVS / Clovis Oncology, Inc. POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on September 5, 2019 Registration No. |
|
| August 23, 2019 |
EX-99.1 Exhibit 99.1 Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Boulder, CO, August 22, 2019 – Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 4.50% Convertibl |
|
| August 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 23, 2019 (August 22, 2019) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporat |
|
| August 20, 2019 |
CLVS / Clovis Oncology, Inc. / Elk Creek Partners, LLC - ELK CREEK PARTNERS, LLC Passive Investment SC 13G 1 clvs82019.htm ELK CREEK PARTNERS, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Clovis Oncology, Inc. (Name of Issuer) Common Stock par Value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) August 15, 2019 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| August 19, 2019 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value $0. |
|
| August 19, 2019 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| August 19, 2019 |
CLVS / Clovis Oncology, Inc. / WHITEBOX ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 19, 2019 |
CLVS / Clovis Oncology, Inc. / D. E. SHAW & CO, L.P. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Clovis Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) August 9, 2019 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedule is |
|
| August 16, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Clovis Oncology, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the und |
|
| August 16, 2019 |
CLVS / Clovis Oncology, Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Clovis Oncology, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 189464100 (CUSIP Number) August 9, 2019 Date of Event Which Requires Fili |
|
| August 13, 2019 |
Clovis Oncology to Offer $225 Million of Convertible Senior Notes EX-99.1 Exhibit 99.1 Clovis Oncology to Offer $225 Million of Convertible Senior Notes Boulder, CO, August 7, 2019 – Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to |
|
| August 13, 2019 |
EX-4.1 Exhibit 4.1 EXECUTION VERSION CLOVIS ONCOLOGY, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of August 13, 2019 4.50% Convertible Senior Notes due 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 10 ARTICLE II ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES 10 Sectio |
|
| August 13, 2019 |
Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes EX-99.2 Exhibit 99.2 Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes Boulder, CO, August 8, 2019 – Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Ac |
|
| August 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2019 (August 7, 2019) Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporati |
|
| August 2, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35347 C |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a52024769.htm CLOVIS ONCOLOGY, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other |
|
| August 1, 2019 |
Clovis Oncology Announces Second Quarter 2019 Operating Results Exhibit 99.1 Clovis Oncology Announces Second Quarter 2019 Operating Results $33.0M in Rubraca® (rucaparib) net product revenue for Q2 2019 compared to $23.8M for Q2 2018 U.S. sales increased 3% sequentially in Q2 2019 over Q1 2019 Global net product revenue guidance of $137 million to $147 million provided for the full year 2019 Updated data from TRITON2 study of patients with BRCA-mutant mCRPC t |
|
| July 8, 2019 |
CLVS / Clovis Oncology, Inc. CORRESP - - CORRESP Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder, CO 80301 July 8, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeff Gabor Re: Clovis Oncology, Inc.—Request for Acceleration Registration Statement on Form S-3 (File No. 333-232503) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the |
|
| July 2, 2019 |
CLVS / Clovis Oncology, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 2, 2019 Registration No. |
|
| July 1, 2019 |
Unregistered Sales of Equity Securities Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commis |
|
| June 15, 2019 |
Unregistered Sales of Equity Securities, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| June 11, 2019 |
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commiss |
|
| June 6, 2019 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLOVIS ONCOLGY, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) THE UNDERSIGNED, being a duly appointed and authorized officer of Clovis Oncology, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the “Corporat |
|
| June 6, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2019 |
Clovis Oncology Announces First Quarter 2019 Operating Results Exhibit 99.1 Clovis Oncology Announces First Quarter 2019 Operating Results $33.1M in Rubraca® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a51980538.htm CLOVIS ONCOLOGY, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other ju |
|
| May 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2019. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-35 |
|
| May 2, 2019 |
EX-10.2 Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT dated as of May 1, 2019 among EACH OF THE GRANTORS PARTY HERETO and TOP IV SPV GP, LLC as Administrative Agent TABLE OF CONTENTS Section 1. DEFINITIONS; GRANT OF SECURITY. 1 1.1 General Definitions 1 1.2 Definitions; Interpretation 9 Section 2. GRANT OF SECURITY. 10 2.1 Grant of Security 10 2.2 Certain Limited Exclusions 11 Section 3. SECURITY FOR |
|
| May 2, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commiss |
|
| May 2, 2019 |
EX-10.1 Exhibit 10.1 FINANCING AGREEMENT dated as of May 1, 2019 among CLOVIS ONCOLOGY, INC. as Company CERTAIN SUBSIDIARIES OF COMPANY as Guarantors AND THE LENDERS FROM TIME TO TIME PARTY HERETO AND TOP IV SPV GP, LLC as Administrative Agent TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 1 Section 1.1. Definitions 1 Section 1.2. Accounting and Other Terms 26 Section 1.3. Interpr |
|
| April 26, 2019 |
CLVS / Clovis Oncology, Inc. DEFA14A DEFA14A DEFA14A 1 d712503ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| April 26, 2019 |
DEF 14A 1 d668722ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| April 24, 2019 |
CLVS / Clovis Oncology, Inc. PRER14A PRER14A 1 d668722dprer14a.htm PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Con |
|
| April 15, 2019 |
CLVS / Clovis Oncology, Inc. PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| April 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2019 Clovis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35347 90-0475355 (State or other jurisdiction of incorporation) (Commission Fi |
